Novel Multi-Targeted Growth Inhibitor Shown Safe but Ineffective at High Doses

A study in Scotland has demonstrated the safety of a novel multi-targeted growth inhibitor (MTGI), ZK 304709, but found it to be ineffective at high doses. The compound, administered orally to 40 patients with advanced solid malignancies, was well-tolerated up to a dose of 360 mg. However, blood concentrations increased only slightly above 90 mg, suggesting that higher doses would not lead to meaningful pharmacological or clinical activity. The study was stopped early due to the lack of further increment in blood concentrations, making it impossible to assess the compound's efficacy or pharmacodynamic endpoints.

Key Takeaways:

• The maximum tolerated dose (MTD) of ZK 304709 was 360 mg, with doses above 90 mg resulting in minimal increase in blood concentrations.
• The compound was safely administered up to 360 mg, but its efficacy was not established due to the trial being stopped early.
• The lack of further increment in blood concentrations above 90 mg suggested that higher doses would not lead to meaningful pharmacological or clinical activity.
• J.S. Graham and colleagues conducted the study at the University of Glasgow, Department of Medical Oncology.
• The study was published in the European Journal of Cancer, an open-access journal.
• ZK 304709 is a novel multi-targeted growth inhibitor with potential anti-cancer properties.

Statistics:

• 40 patients with advanced solid malignancies were treated with ZK 304709.
• The dose escalation schedule involved 7 days of treatment followed by 14 days of recovery.
• Doses were increased in sequential cohorts of three patients, with expansion to 6-7 patients if a dose-limiting toxicity occurred.
• Blood concentrations of ZK 304709 increased only slightly above 90 mg.

Sources:

• European Journal of Cancer (2008;44(15):2162-2168)
• University of Glasgow, Department of Medical Oncology
• Cancer Research UK
• European Journal of Cancer, published by Elsevier Science Ltd.